Monitoring and Management of Adverse Effects

Laboratory Monitoring

Recheck calcium, liver enzymes, and renal function in 2-4 weeks, as recommended by the American Academy of Dermatology 1
For persistent elevation in liver enzymes during a 12-month period or decline in serum albumin below normal range, consider GI consultation and/or liver biopsy, according to the American Academy of Dermatology 1
Use the fibrosis-4 (FIB-4) index to stratify patients into low, intermediate, and high risk of advanced fibrosis, with FIB-4 < 1.3 indicating low risk, FIB-4 1.3-2.67 indicating intermediate risk, and FIB-4 > 2.67 indicating high risk, as recommended by the American Association for the Study of Liver Diseases 2
The following FIB-4 score table is used for fibrosis risk assessment:

Calculate NAFLD Fibrosis Score to identify patients with higher likelihood of bridging fibrosis or cirrhosis, as suggested by the American Gastroenterological Association and the American Association for the Study of Liver Diseases 3, 4
Abdominal ultrasound is recommended as the initial imaging evaluation for patients with mildly elevated liver enzymes, tenderness, and history of vomiting to help confirm or exclude hepatitis, with a specificity of 71-97% for confirming the absence of mechanical biliary obstruction, as suggested by the American College of Radiology 5 and the American Association for the Study of Liver Diseases 6

Simplify diabetes treatment regimens to minimize hypoglycemia risk, prioritizing regimens with low hypoglycemia risk, and avoiding medications that may worsen liver function, as recommended by the American Diabetes Association 7
Consider GLP-1 receptor agonists, such as semaglutide, which may improve steatosis and some features of NASH, but require careful consideration of overall health status 8
Monitor closely for hypoglycemia, particularly in elderly patients, and avoid aggressive glucose targets 7

Implement lifestyle modifications with realistic goals for age, including a Mediterranean diet pattern, moderate calorie restriction, and regular, gentle physical activity as tolerated, as recommended by the American Gastroenterological Association 9
Aim for 150-300 minutes of moderate-intensity exercise weekly, if possible, to reduce hepatic steatosis 9
Focus on lifestyle modifications with weight loss of at least 3-5% of body weight through diet and exercise as the first-line treatment, as recommended by the American Gastroenterological Association and the American Association for the Study of Liver Diseases 3, 4

Assess for other components of metabolic syndrome, and consider a 75g oral glucose tolerance test to better characterize diabetes 10
Test for autoimmune markers (ANA, ASMA, immunoglobulins) in patients with liver disease, as recommended by the American Association for the Study of Liver Diseases 11
Perform a viral hepatitis panel (HAV-IgM, HBsAg, HBcIgM, HCV antibody) as first-line serologic testing, as recommended by the American Gastroenterological Association 12
Fractionation of bilirubin can help determine if hyperbilirubinemia is predominantly direct (conjugated) or indirect (unconjugated), with direct bilirubin >35% of total suggesting liver disease or biliary obstruction, and indirect bilirubin predominance indicating possible Gilbert's syndrome or hemolysis, as recommended by the American Gastroenterological Association 13

Patients with alcohol-related liver disease should undergo complete alcohol cessation, nutritional support, and consider thiamine supplementation, as recommended by the American Association for the Study of Liver Diseases 2
HIV patients with elevated liver enzymes should be evaluated for medication toxicity, opportunistic infections, viral hepatitis co-infection, and alcohol use, as recommended by the American Family Physician 14
Hepatitis B patients should be monitored closely, with antiviral therapy and close monitoring of liver enzymes, as recommended by the American Association for the Study of Liver Diseases 2
Hepatitis C patients should be referred for antiviral therapy evaluation and monitored for post-treatment flares, as suggested by the European Association for the Study of the Liver 2
Patients with cirrhosis should undergo hepatocellular carcinoma surveillance with ultrasound every 6 months, as recommended by the American Association for the Study of Liver Diseases 2

Measure liver enzymes approximately every 3-4 months for stable doses in patients on medications with potential hepatotoxicity (e.g., methotrexate), as recommended by the American College of Rheumatology 15
Decrease medication dose or temporarily withhold for liver enzyme elevation > 2× ULN, and discontinue medication for elevation > 3× ULN despite dose reduction, as recommended by the American College of Rheumatology 15
For patients with grade 2 immune-mediated hepatitis (ALT/AST 3-5× ULN), temporarily withhold immunotherapy and consider corticosteroids (CS) 0.5-1 mg/kg/day, as recommended by the European Society for Medical Oncology 16
For patients with grade 3-4 immune-mediated hepatitis (ALT/AST >5× ULN), permanently discontinue immunotherapy and start CS 1-2 mg/kg/day, as recommended by the European Society for Medical Oncology 16 and the American Society of Clinical Oncology 17

Long-term monitoring is essential as NAFLD can progress over time, with follow-up intervals depending on risk category, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 18, 10, 2
Ongoing monitoring should include both hepatic and metabolic parameters, such as liver enzymes, fasting glucose/HbA1c, lipid profile, blood pressure, and BMI/waist circumference, as recommended by the American Association for the Study of Liver Diseases 10